Académique Documents
Professionnel Documents
Culture Documents
502
2013 BY
RIGHTS RESERVED.
0002-9394/$36.00
http://dx.doi.org/10.1016/j.ajo.2013.04.026
METHODS
THE CURRENT STUDY IS A PROSPECTIVE RANDOMIZED CLIN-
503
photocoagulation or continue to receive the same intravitreal medication for an additional 3 consecutive visits.
FOLLOW-UP
EXAMINATIONS
AND
OUTCOME
MEASURES: Patients were scheduled for follow-up examina-
RESULTS
A TOTAL OF 48 PATIENTS WITH CENTER-INVOLVED DME IN
SEPTEMBER 2013
TABLE 1. Baseline Characteristics of Patients Treated With Intravitreal Bevacizumab Versus Ranibizumab for the Management of
Diabetic Macular Edema
Baseline Characteristics
Bevacizumab Group
Ranibizumab Group
63.8 6 8.8
13/19
4/4/24
16.2 6 8.0
23
9
13
19
8.6 6 1.3
139.3 6 16.5
78.6 6 11.2
1.41 6 0.87
19
13
63.7 6 9.0
14/14
6/4/18
15.9 6 8.0
21
7
13
15
8.7 6 2.0
143.1 6 20.1
80.5 6 11.9
1.51 6 0.78
17
11
TABLE 2. Mean and Standard Error for Best-Corrected Visual Acuity and Central Subfield Thickness in the Intravitreal Bevacizumab
and Intravitreal Ranibizumab Groups for the Management of Diabetic Macular Edema, During 48-Week Follow-up Period
Best-Corrected Visual Acuity (logMAR)
IV Bevacizumab
IV Ranibizumab
0
4
8
0.60 6 0.05
0.48 6 0.06
0.48 6 0.06
0.63 6 0.06
0.53 6 0.06
0.46 6 0.06
.6613
12
16
20
24
28
0.45 6 0.05
0.42 6 0.05
0.41 6 0.05
0.41 6 0.05
0.43 6 0.06
0.46 6 0.05
0.43 6 0.06
0.42 6 0.06
0.40 6 0.05
0.40 6 0.05
.0659
32
0.41 6 0.06
0.36 6 0.04
.0415
351.1 6 19.5
295.6 6 15.5
.3091
36
0.40 6 0.06
0.36 6 0.04
.0543
344.5 6 20.6
287.7 6 14.7
.3173
40
0.39 6 0.06
0.35 6 0.04
291.2 6 10.4
.2315
0.36 6 0.05
0.36 6 0.05
0.34 6 0.04
0.34 6 0.04
.0635
.1326
.1886
354.0 6 21.5
44
48
339.8 6 19.5
329.7 6 19.3
281.2 6 14.3
280.9 6 12.6
.2843
.4865
Week
.0318
.1893
.2481
.2590
.1457
IV Bevacizumab
IV Ranibizumab
451.7 6 22.3
385.3 6 20.9
357.2 6 17.6
421.9 6 23.1
328.9 6 18.0
313.9 6 15.2
.2615
.4407
347.3 6 17.5
347.6 6 17.7
343.6 6 20.5
342.8 6 18.4
352.1 6 20.1
309.3 6 18.0
316.8 6 14.5
304.0 6 17.9
300.4 6 12.4
293.9 6 13.9
.5106
.6035
.4934
.4584
.2839
IV intravitreal.
a
Dark gray background highlights P < .05; light gray background highlights P < .10.
505
SEPTEMBER 2013
FIGURE 3. Proportion of eyes with diabetic macular edema treated with intravitreal (IV) bevacizumab (black bars) and ranibizumab
(white bars) with central subfield thickness 275 mm. The proportion was significantly higher in the IV bevacizumab group at weeks
4 (P [ .029), 28 (P [ .007), 36 (P [ .0028), and 44 (P [ .029) (likelihood ratio) when compared with the IV ranibizumab group.
DISCUSSION
IN THE PRESENT STUDY, BOTH GROUPS ACHIEVED SIGNIFI-
507
SEPTEMBER 2013
ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST.
Rodrigo Jorge received travel support from Novartis to attend the 2012 American Society of Retina Specialists (ASRS) meeting. This study was supported
by Fundacao de Amparo a` Pesquisa do Estado de Sao Paulo (FAPESP), grant number 2010/013368; and Fundacao Apoio ao Ensino, Pesquisa e Assistencia
(FAEPA) do Hospital das Clnicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo. Contributions of authors: conception and
design of the study (I.U.S., A.M., R.C.S., R.J.); analysis and interpretation (A.B.N., E.T., F.P.P.A., R.P., R.C.S., J.A.C., A.M., I.U.S., R.J.); writing the
article (A.B.N., E.T., F.P.P.A., R.P., J.A.C., A.M., I.U.S., R.J.); critical revision (A.B.N., J.A.C., R.C.S., I.U.S., A.M., R.J.); final approval of the article
(A.B.N., E.T., F.P.P.A., R.P., R.C.S., J.A.C., A.M., I.U.S., R.J.); data collection (A.B.N., E.T., F.P.P.A., R.P., R.C.S.); provision of materials (A.B.N.,
E.T., F.P.P.A., R.P., R.C.S., J.A.C., R.J.); statistical analysis (A.M., R.J.); obtaining funding (A.B.N., E.T., A.M., R.J.); literature search (A.B.N., E.T.,
R.C.S., I.U.S., R.J.); and administrative, technical, or logistic support (A.B.N., J.A.C., A.M., R.J.). This trial was registered at clinicaltrials.gov under
number: NCT01487629.
The authors would like to thank Prof Dr Klaus Dietz, professor emeritus of Medical Biometry (University of TubingenGermany), for review of and
constructive comments on the statistical analysis.
REFERENCES
1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes.
Ophthalmology 1984;91(1):19.
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The
Wisconsin epidemiologic study of diabetic retinopathy.
IV. Diabetic macular edema. Ophthalmology 1984;91(12):
14641474.
3. Early Treatment Diabetic Retinopathy Study Research
Group. Photocoagulation for diabetic macular edema. Early
Treatment Diabetic Retinopathy Study report number 1.
Arch Ophthalmol 1985;103(12):17961806.
4. Elman MJ, Raden RZ, Sloan MD, et al. Randomized trial
comparing intravitreal triamcinolone acetonide and focal/
grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115(9):14471459.
5. Googe J, Brucker AJ, Bressler NM, et al. Randomized trial
evaluating short-term effects of intravitreal ranibizumab or
triamcinolone acetonide on macular edema after focal/grid
laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31(6):10091027.
6. Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic
macular edema. Ophthalmology 2007;114(10):18601867.
7. Scott IU, Danis RP, Bressler SB, Bressler NM, Browning DJ,
Qin H. Diabetic Retinopathy Clinical Research Network.
Effect of focal/grid photocoagulation on visual acuity and
8.
9.
10.
11.
12.
13.
14.
509
15.
16.
17.
18.
19.
20.
21.
510
22. Grover S, Murthy RK, Brar VS, Chalam KV. Normative data
for macular thickness by high-definition spectral-domain
optical coherence tomography (Spectralis). Am J Ophthalmol
2009;148(2):266271.
23. Menke MN, Dabov S, Knecht P, Sturm V. Reproducibility of
retinal thickness measurements in healthy subjects using
spectralis optical coherence tomography. Am J Ophthalmol
2009;147(3):467472.
24. Lovestam-Adrian M, Agardh E. Photocoagulation of diabetic
macular oedemacomplications and visual outcome. Acta
Ophthalmol Scand 2000;78(6):667671.
25. Elman MJ, Bressler NM, Qin H, et al. Diabetic Retinopathy
Clinical Research Network. Expanded 2-year follow-up of
ranibizumab plus prompt or deferred laser or triamcinolone
plus prompt laser for diabetic macular edema. Ophthalmology
2011;118(4):609614.
26. Filho JA, Messias A, Jorge R, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for highrisk proliferative diabetic retinopathy. Acta Ophthalmol 2011;
89(7):e567e572.
27. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained
increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular agerelated macular degeneration. J Glaucoma 2012;21(4):
241247.
28. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight
aggregates in repackaged bevacizumab. Retina 2010;30(6):
887892.
SEPTEMBER 2013
Biosketch
Antonio Brunno Nepomuceno received his medical degree from the Federal University of Ceara, Fortaleza, Brazil. In 2011,
he completed his ophthalmology residency and started working as a retinal fellowship trainning at the School of Medicine
of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil. His primary research interests pertain to diabetic
retinopathy, macular edema and anti-VEGF agents.
510.e1
Biosketch
Rodrigo Jorge is an Associate Professor and coordinates the Postgraduate program in the Ophthalmology Department and
in the Retina and Vitreous Division in Clinics Hospital, School of Medicine of Ribeirao Preto, University of Sao Paulo. He
has taught and published in the field of vitreoretinal diseases, with over 80 publications. Since 2006, his research has focused
on anti-VEGF therapy studies and his collaborative study group has published the most cited prospective studies of agerelated macular degeneration and diabetic retinopathy conceived and conducted in Brazil.
510.e2
SEPTEMBER 2013